Key Developments: Dr.Reddy's Laboratories Ltd (RDY)

RDY on New York Consolidated

45.33USD
23 Jul 2014
Price Change (% chg)

$0.10 (+0.23%)
Prev Close
$45.23
Open
$45.29
Day's High
$45.46
Day's Low
$45.06
Volume
138,780
Avg. Vol
362,093
52-wk High
$47.93
52-wk Low
$31.32

Search Stocks

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Laboratories Ltd announces launch of Duloxetine Delayed-Release Capsules USP
Friday, 27 Jun 2014 03:27am EDT 

Dr.Reddy's Laboratories Ltd:Launched Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg, therapeutic equivalent generic version of CYMBALTA((reg))(Duloxetine Delayed-Release Capsules) in US market on June 26.Dr. Reddy's ANDA is approved by US Food & Drug Administration.  Full Article

Dr.Reddy's Laboratories Ltd launches Paricalcitol Capsules
Wednesday, 25 Jun 2014 02:01am EDT 

Dr.Reddy's Laboratories Ltd:Says the launch of Paricalcitol Capsules.  Full Article

Dr.Reddy's Laboratories Ltd recalls over 13,000 bottles of hypertension drug in US-Business Standard
Thursday, 19 Jun 2014 03:30am EDT 

Dr.Reddy's Laboratories Ltd:Is recalling 13,560 bottles of the high blood pressure drug Metoprolol succinate in the United States after it failed a dissolution test, the U.S. Food and Drug Administration said-Business Standard.The recall was voluntarily started by Dr Reddy's on May 23, 2014.A Dr Reddy's spokesman did not immediately respond to a request for comment on the recall.  Full Article

Dr.Reddy's Laboratories Ltd announces changes in levels
Tuesday, 13 May 2014 04:35am EDT 

Dr.Reddy's Laboratories Ltd:Appoints Sathish Reddy as Chairman of the Board, he was previously held position of Vice Chairman, Managing Director & COO.GV Prasad will continue as CEO and provide leadership to the company in an Executive role.Prasad has been appointed as Co-Chairman and Managing Director.  Full Article

Dr.Reddy's Laboratories Ltd recommends final dividend
Tuesday, 13 May 2014 04:09am EDT 

Dr.Reddy's Laboratories Ltd:Recommends final dividend of 18 Indian rupees (360 pct) per equity share of five Indian rupees face value, for the FY 2013-14.Dividend on equity shares, if declared by the shareholders at the ensuing annual general meeting, will be credited / despatched on or after Aug. 07.  Full Article

Dr.Reddy's Laboratories Ltd launches Fenofibrate Capsules
Wednesday, 23 Apr 2014 12:55am EDT 

Dr.Reddy's Laboratories Ltd:Launches Fenofibrate Capsules, USP 43 mg and 130 mg a therapeutic equivalent generic version of ANTARA (fenofibrate) capsules, in the US market on April 22 approved by the United States Food & Drug Administration (USFDA).ANTARA (fenofibrate) capsules brand and generic had U.S. sales of about $74 Mln MAT for the most recent twelve months ending in Feb 2014 according to IMS Health.Says Fenofibrate capsules, USP 43 mg is available in bottle counts of 30 and 130 mg are available in bottle counts of 30 and 90.  Full Article

Dr.Reddy's Laboratories Ltd announces the launch of Eszopiclone Tablets
Wednesday, 16 Apr 2014 12:43am EDT 

Dr.Reddy's Laboratories Ltd:Launch of Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA (eszopiclone) tablets C-IV in the US market on April 15.Approval by the United States Food & Drug Administration (USFDA).Dr. Reddy's Eszopiclone Tablets (C-IV) 1 mg is available in bottle counts of 30. Eszopiclone Tablets (C-IV) 2 mg and 3 mg are available in bottle counts of 100.  Full Article

Dr.Reddy's Laboratories Ltd announces launch of Moxifloxacin Hydrochloride tablets
Wednesday, 5 Mar 2014 02:22am EST 

Dr.Reddy's Laboratories Ltd:Launched Moxifloxacin Hydrochloride Tablets, 400 mg, therapeutic equivalent generic version of Avelox (moxifloxacin HCl) tablets 400 mg in the U.S. market on March 04.Following approval by the United States Food & Drug Administration (USFDA).  Full Article

Dr.Reddy's Laboratories Ltd announces launch of Sumatriptan Injection USP, autoinjector systemi
Wednesday, 26 Feb 2014 12:43am EST 

Dr.Reddy's Laboratories Ltd:Has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL For Subcutaneous Use.Says injection was launched In the US market on Feb. 25, 2014, following the approval by the United States Food & Drug Administration.  Full Article

Dr.Reddy's Laboratories Ltd Faces Patent Infringement Suit - Business Standard
Tuesday, 5 Nov 2013 09:34am EST 

Business Standard reported that the Teijin Limited, owner of the US patent of hyperuricemia drug febuxostat, along with the two licence holders of the patent, has filed an infringement suit against Dr.Reddy's Laboratories Ltd for seeking to manufacture and sell a generic version of the drug in the US before the expiration of the patent.  Full Article

Search Stocks